
Share
Revenue climbed 49% to $890.4 million, but a swing to net loss, a third straight EPS miss, and gross margin that fell from 74% to 57% signal the real cost of chasing branded weight-loss drugs.
Hims & Hers posted $890.4 million in third-quarter revenue, up 49% from $599 million a year earlier. That top-line number looks strong on its face. The details underneath it do not.
The telehealth company swung to a net loss of $33 million, reversing $15.8 million in profit from the same quarter last year. It also missed Wall Street's earnings estimate for the third consecutive quarter, losing 14 cents a share against an expected gain of six cents. In response, management tightened full-year 2026 revenue guidance to a range of $3.13 billion to $3.15 billion and cut adjusted EBITDA guidance to between $257 million and $277 million.
Gross margin tells the sharper story. It fell to 57%, down from 74% a year ago. Ethan Feller, stock strategist at Zacks Investment Research, pointed to the cause directly: more of the business is shifting toward lower-margin, brand-name weight-loss drugs. U.S. growth actually accelerated to 21%, and revenue came in roughly where analysts expected. But profitability did not follow.
CFO Yemi Okupe offered a partial explanation for the guidance cut, citing "more aggressive strategic pricing and marketing actions" planned for the U.K. and Germany, alongside a deferral tied to the company's weight loss membership offering. Revenue excluded $18 million from the "scaling of membership revenue" in that segment, which Okupe said will be recognized in the fourth quarter instead. He was careful to note the deferral "has no impact on free cash flow generation."
Subscriber growth remained healthy. Hims & Hers closed the quarter with nearly 2.8 million subscribers, up 13% year-over-year. Adjusted EBITDA ticked up slightly to $82.4 million from $78.4 million. Those figures support the long-term demand story. They do not explain away the margin compression that's now showing up quarter after quarter.
The company's strategic pivot is clear enough. CEO Andrew Dudum is betting on scale, pharmacy and lab infrastructure, and an "AI-native experience" to drive efficiencies even as the drug mix shifts toward pricier, lower-margin branded products. He flagged testosterone replacement therapy launching this quarter and a Peptides Plus offering later this month, continuing a push into sermorelin, NAD+, and other already-permitted peptides that Dudum first previewed to investors last quarter.
The company also struck a deal with Eli Lilly to offer its branded obesity treatments directly through the Hims & Hers platform, a notable shift. Those drugs were previously accessible only if patients left the site for Lilly's own direct-to-consumer platform, LillyDirect. Dudum framed the partnership as validation of the company's reach: "Nearly 3 million people across four continents rely on us to access care," he said, adding that this trust "has made us a valuable partner to global pharmaceutical leaders like Novo and Lilly."

Having both Novo Nordisk and Lilly on the platform is a genuine competitive advantage. It gives Hims & Hers access to branded demand that smaller telehealth rivals simply cannot match. But branded drugs carry branded pricing, and that pricing is now visibly compressing the company's margin structure. Dudum also outlined plans for "flexible multi-month subscriptions" across the platform's product assortment, aimed at making it easier for customers to commit to longer-term health goals, alongside an AI-native experience he said will soon reach nearly every weight loss customer.
Feller's read on the setup is measured rather than bearish. "The company's growth story is still a real long-term tailwind," he said. "Demand for weight-loss drugs is strong, and having both Novo and Lilly on the platform helps." His caveat matters more than the compliment. "As long as margins keep shrinking, the stock will likely stay under pressure until either the price falls to a level that reflects the lower margins or the company shows it can turn a steady profit."
That is the crux of the investment case right now. Hims & Hers is not struggling to grow. It is struggling to grow profitably while its product mix shifts toward branded pharmaceuticals that carry thinner margins than its historical generic and compounded offerings. Three consecutive EPS misses is not noise. It is a pattern, and patterns tend to get priced in eventually.
Dudum's framing leans on a three-part long-term strategy: leadership in domestic and global metabolic health, dominance in major global markets, and staying "at the forefront of category expansion." He described these as mutually reinforcing, arguing together they describe "how Hims & Hers becomes the global destination for consumer health." It's an ambitious vision, and the subscriber and revenue numbers suggest real customer demand behind it. Whether that vision converts into durable profit is the open question the market has not yet answered.
Watch gross margin first. A second straight year-over-year decline of this magnitude, from 74% to 57%, would confirm that the branded drug pivot is structurally reshaping the business model, not just creating a temporary bump. Watch the U.K. and Germany pricing actions Okupe flagged, since aggressive international pricing moves tend to pressure margins further before they stabilize market share. And watch whether the $18 million deferred membership revenue actually materializes in Q4 as promised, since any slippage there would raise fresh questions about revenue recognition discipline.
The subscriber base is growing, the pharma partnerships are expanding, and U.S. growth is accelerating. None of that changes the fact that the company has missed earnings estimates three quarters running while its core profitability metric erodes. Investors betting on the long-term metabolic health thesis need to be comfortable with near-term margin pain, because right now there is no clear catalyst suggesting that pain reverses soon.
Tags
Original Sources
Hims & Hers reports $890.4M Q3 revenue, tightens 2026 outlook
↗ https://www.fiercehealthcare.com/finance/hims-hers-reports-8904m-q3-revenue-tightens-2026-outlook
About the author
Marcus began tracking AI's market implications in 2016, noticing AI-related patent filings accelerating ahead of earnings upgrades before most of the sell-side had caught on. A former fixed-income quantitative analyst, he spent two decades building models that priced risk across emerging markets before pivoting to cover the economic impact of AI full-time. His writing translates opaque technical developments into clear risk/reward terms — and he's rarely diplomatic about the gap between AI valuations and underlying fundamentals. He believes most market participants still underestimate AI's long-run deflationary effect on knowledge work.
More from The Analyst →This Week's Edition
11 November 2026
14 articles
Related Articles
Related Articles
More Stories
© 2026 Cedar & Bloom. All rights reserved.